2025-521166-95-00Not yet recruitingPhase 2
TMSxDCS: Medicinal improvement of brain stimulation for depression.
TMSxDCS: Pharmacologically augmenting transcranial magnetic stimulation for depression
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Sept 2026
Brief summary (registry, in English)
The primary objective of this study is to investigate the antidepressive effect of augmenting a single day of accelerated transcranial magnetic stimulation (TMS) with D-cycloserine (DCS).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 19 Feb 2025
- Start date
- 17 Aug 2026
- Lead sponsor
- Universiteit Maastricht
- Diseases
- Depression
- EU CT number
- 2025-521166-95-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 48
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with major depression that has not improved enough with at least 2 antidepressant medicines. It tests brain stimulation (TMS) together with the medicine D-cycloserine.
- Age
- 18 to 65 years (the record also lists a maximum age of 64 years)
- Sex
- All sexes can join.
- Disease stage
- Major depressive disorder, a current moderate to severe episode (MADRS score above 20), treatment resistant.
- Earlier treatment
- Has tried at least 2 types of antidepressant medicine without enough effect. No change in antidepressant treatment (medicine or psychotherapy) in the 4 weeks before joining.
Main reasons for not taking part
- Pregnancy at joining or during the study
- Metal implants or a cochlear implant near the head
- Bipolar disorder, psychosis or schizophrenia in the past, or another main psychiatric diagnosis
- Kidney insufficiency in the past or current substance abuse disorder
- Use of olanzapine, clozapine, ethionamide or isoniazid, or regular scheduled use of benzodiazepines
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any change in antidepressant treatment (medication, psychotherapy) 4 weeks prior to enrollment
- Has a cochlear implant
- Metal implants near (<10 cm away from coil) the head including: - Aneurysm clips / coils - Any medical implant containing metal near the head - Metal stents in the brain - Shrapnel or bullet fragments - Implanted vagus nerve or deep brain stimulators, Electrodes for monitoring brain activity
- Current scheduled use of benzodiazepines (as needed use is permitted, except for the day prior to treatment)
- Current use of any of the following medications: Olanzapine, clozapine, ethionamide, isoniazid
Other illness
- Primary psychiatric diagnosis other than MDD
- A history of bipolar disorder
- A history of psychosis
- A history of schizophrenia
- A history of renal insufficiency
- Current substance abuse disorder
Other
- Pregnancy upon inclusion or during the study period, though women with childbearing potential will be included into the study.
Who the study is looking for
- A primary diagnosis of MDD, with a current moderate to severe depressive episode (score of >20 on the MADRS)
- Age between 18-65 years old
- A diagnosis of moderate to severe measures of treatment resistant depression (TRD) and have tried at least 2 types of antidepressant medication without sufficient result
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brain Modulation | Maastricht | Netherlands | Not yet recruiting |
| Universiteit Maastricht | Maastricht | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.